The new coronary pneumonia vaccine can be applied at the end of the year, and the specific drugs are more difficult to develop than the vaccine
In the past few months, the development of several strategies for vaccines has been moving forward. Wu Zunyou said that the results of the current phase 1 and 2 clinical trials are encouraging. By the end of the year, the application of vaccines will not be a big problem, but because of the ease of There are many people who feel that there is a need to be cautiously optimistic about the vaccine. The biggest problem is the production capacity and whether the vaccine has long-term immunity.